A method to quantify and assess the dosimetric and clinical impact resulting from the heterogeneity correction in radiotherapy for lung cancer by Chaikh, Abdulhamid et al.
International Journal of Cancer Therapy and Oncology
www.ijcto.org
Copyright © Chaikh et al. ISSN 2330-4049
Abdulhamid Chaikh1, 2, Jean-Yves Giraud1, 2, Jacques Balosso1, 2
1University Joseph Fourier, Grenoble, France.
2Department of Radiation Oncology and Medical physics, Grenoble University Hospital, France.
Received January 03, 2014; Revised January 27, 2014; Accepted January 27, 2014; Published Online January 30, 2014
Original Article
Abstract
Purpose: The aim of this study was to propose a method to quantify and assess the differences in dose computations using het-
erogeneity correction algorithms for the planning target volumes and organs at risk. Methods: Six patients with lung cancer
treated with 3-dimensional conformal radiation therapy were included and analysed. Dose calculations were performed using the
pencil beam convolution (PBC) algorithm without heterogeneity correction and the Modified Batho method (PBC-MB) with
heterogeneity correction. For each patient, 3 treatment plans were generated using exactly the same beam configuration. In plan
1, the dose was calculated using the PBC algorithm. In plan 2, the dose was calculated using the PBC-MB. In plan 3, the dose was
calculated using the PBC-MB method but with the same number of monitor units obtained from plan 1. To evaluate the treat-
ment plans computed by the PBC and PBC-MB, the monitor units, dose at the isocenter, spatial isodose distribution, dose volume
histograms, conformity index, homogeneity index, planning target volumes conformity index, and geometrical index were
compared. A statistical analysis was carried out using Wilcoxon signed rank test. Results: The PBC-MB method in plan 2 pro-
duced a lower number of monitor units than in plan 1 using PBC algorithm (p < 0.001). Dosimetric parameters derived from the
dose volume histograms were higher for the planning target volumes and organs at risks using PBC-MB method for plans 2 and 3
when compared to plan 1. There was no significant difference for all the quality indices between plan 1 and plan 2, (p > 0.05), but
a significant difference for the geometric index between plans 2 and 3 (p = 0.002) was observed. Conclusion: The risks related to
the modification from the homogeneity plan to the heterogeneity plan were the reduction of delivered dose in monitor units for
the planning target volumes and the increment of the dose to the organs at risk. We suggest the adaption in the dose prescriptions
when switching the dose calculation algorithm from the PBC to PBC-MB.
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Introduction
Treatment planning is one of the main steps in radiotherapy,
and it typically includes the isodose distributions and dose vol-
ume histograms (DVH) for the target volume and critical struc-
tures. The dose calculation in radiation therapy is performed
using the algorithms employed in the treatment planning system
(TPS). In a homogenous plan, the algorithms assume the patient
has homogenous tissue density; whereas in a heterogeneous plan
the algorithm takes into account the different densities of the
tissues. For clinical use, the algorithms must calculate the dose
as accurately as possible. Several studies have evaluated the dose
calculation algorithms for external photon beam therapy.1, 2, 3
They showed that the choice of algorithm could produce a large
impact on the dose distribution. Additionally, a number of stud-
ies have assessed the impact of heterogeneity correction on dose
calculations for lung cancer showing a large impact on the dose
calculation.4, 5, 6 It was concluded that the heterogeneity correc-
tion algorithms were not equivalent in their ability to calculate
the dose for lung cancer patients. The aim of this study is to
introduce a method for investigating the dosimetric and clinical
impact of heterogeneity correction in lung cancer patients. We
quantified and assessed the impact of the tissue heterogeneity
correction in terms of monitor units (MUs), spatial isodose dis-
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tribution, and dosimetric parameters derived from cumulative
DVH (cDVH). We also introduced the differential DVH (dDVH)
and quality indices to evaluate the impact of heterogeneity cor-
rection on the dose distributions.
Methods and Materials
Dose calculation algorithm
Dose calculation in this study is based on pencil beam convolu-
tion (PBC) algorithm, which has been integrated in the Eclipse®
TPS (Version 8.1; Varian Medical Systems, Palo Alto, CA). The
PBC algorithm includes two calculation modes: without hetero-
geneity correction (hereafter referred as PBC), and with hetero-
geneity correction using a Modified Batho (hereafter referred as
PBC-MB) method. Heterogeneity correction is typically based
on the relative electron densities obtained from the computed
tomography (CT)-Scan. The PBC-MB method employs an em-
pirical correction factor that uses the tissue maximum ratios, and
it takes into account the heterogeneity correction in 1D. The
PBC algorithm considers the lateral scattering to calculate the
dose for the homogeneous media. The heterogeneity correction
is only applied in the longitudinal direction. The PBC-MB ac-
counts the heterogeneity by using the equivalent path length
converted from mass attenuation. The principle of PBC-MB is
first to calculate a relative dose distribution within a medium of
homogeneous water-equivalent composition, and then to add an
inhomogeneity correction factor. This factor makes adjustments
to the uncorrected distribution to account for variations in tissue
density.7, 8, 9, 10, 11 All dose calculations in this study were done
using a grid size was 2.5 mm.
Clinical cases
This study is based on the dosimetric data of six patients treated
for the lung cancer, which included a total of fourteen planning
target volumes (PTVs). The patients were treated using the 3D
radiotherapy irradiation technique with 18 mega-voltage (MV)
photon beams. Table 1 shows the site locations, the number of
PTVs, the prescribed dose, and the treatment fields for all six
patients.
Contouring
For the treatment planning, the CT dataset of each clinical case
were used. Physicians delineated the anatomic borders of target
structures and organs at risk (OARs). The PTVs were defined
according to the recommendations of ICRU Reports 50 and 62.12,
13 The PTVs were expanded from the clinical target volume with
a margin to account for uncertainties in beam alignment, patient
positioning, organ motion, and organ deformation. The virtual
simulation for each patient was generated by a Digitally Recon-
structed Radiograph (DRR) and Beam's Eye View (BEV) infor-
mation.
Treatment planning
For each patient, 3 treatment plans were generated using exactly
the same configuration of beams, collimator, and accessories. In
plan 1, the dose was calculated using the PBC without the het-
erogeneity correction. In plan 2, the dose was calculated using
the PBC-MB method for the heterogeneity correction. In plan 3,
the dose was calculated using the PBC-MB method but with the
same number of MUs as obtained from plan 1. In all plans, the
dose was prescribed at a single reference point as recommended
by the ICRU Reports 50 and 62.12, 13 The reference treatment
plans were designed according to the clinical experience of the
department and ICRU recommendations.12, 13 Figure 1 shows the
CT-Scan for the parenchyma site (Patient # 1). The red and yel-
low circles show the PTV2 with a field size of 5.4 × 5.3 cm² and
the PTV1 with a field size of 6.4 × 6.4 cm², respectively. In this
case, the patient was treated using 6 treatment fields. Specifical-
ly, each PTV was treated using three fields: one lateral and two
oblique.
For each patient, to compare plan 2 with plan 1, the calculated
dose in plan 1 was taken as the reference value. The percentage
difference was calculated as: D2-D1Dose (%) = ×100          (1)D1
For each patient, to compare plan 3 with plan 2, the calculated
dose in plan 2 was taken as the reference value. The percentage
difference was calculated as: D3-D2Dose (%) = ×100         (2)D2
Dosimetric analysis
MUs and isocenter dose
For each field in a given patient case, the MUs comparison was
done between the plan 1 and plan2 for each field. The isocenter
dose calculated by the PBC-MB in plan 3 was compared to that of
prescribed dose in plan 1.
Spatial isodose distribution
The isodose curves at 40%, 95%, and 100 % were compared plans
1, 2, and 3.
DVH
For each PTV, the maximum dose, minimum dose, mean dose,
dose to 95% of the PTV volume (D95), and the volume of PTV
receiving at least 95% of the prescribed dose (V95) were com-
pared using cDVH. The dDVH was used to compare the dose
homogeneity inside the PTV using the standard deviation asso-
ciated with the dDVH. For the normal lung, (i.e., lung - PTV),
the maximum dose, minimum dose and mean dose were com-
pared. Additionally, the comparison was done for the volume
fractions of normal lung receiving 10, 13, 20, and 30 Gy (V10,
V13, V20, and V30 Gy, respectively). For the spinal cord, the
maximum dose was compared.
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TABLE 1: Characteristics of the 6 patients treated with 3D radiotherapy using a 18 MV photon beam, tumour location, volume of PTVs, dose
prescription, and treatment fields. The PTVs number shows the multiple PTVs for the same case.




Number of Treatment fields
1 Right parenchyma 1 75 50 3
2 38 16 3
2 Left retro cardiac 1 618 50 9
2 329 10 4
3 150 6 4
3 Top left lung 1 343 50 4
2 207 14 3
3 102 6 3
4 Mediastina 1 332 50 5
2 115 10 4
5 Mediastina 1 616 50 8
2 295 10 4
6 Oesophagus 1 1136 45 4
2 554 9 4
FIG. 1: CT-Scan for the parenchyma site (Patient # 1). The red and
yellow circles show PTV2 with a field size 5.4 × 5.3cm² and PTV1
with a field size 6.4 × 6.4cm², respectively.
Quality indices
The following quality indices were calculated and com-
pared.14, 15:
The Conformity Index (CI) was used to compare the plan
conformity, defined as:
Minimum dose encompassing the PTVCI =     (3)
Prescribed Dose
The Homogeneity Index (HI) was used to compare the dose
homogeneity in the PTV, defined as:
Maximum Dose in the PTVHI =           (4)  
Prescribed Dose
The PTV Conformity Index (CIPTV) was used to compare the
degree of conformity of the prescribed dose, defined as:
V95CIPTV =          (5)
PTV volume 
where, V95 is the PTV volume receiving more than 95% of
the prescribed dose.
The geometrical index (g) was used to compare the geometric
conformity to the PTV and normal tissues, defined as:
VPTV  VNT            (6)
PTV volume 
  g 
where VPTV designates the PTV volumes receiving a dose
lower than 100% of the prescribed dose and VNT are the
normal tissue volumes receiving 100% of the prescribed dose.
Statistical analysis
The Wilcoxon signed rank test was used to calculate the
p-value using an alpha error at 5%. Data are presented as
average ± standard deviation (SD).
Results
MUs and isocenter dose
The PBC-MB in plan 2 calculated significantly less MUs than
the PBC in plan 1 by on average 5.2% (4.4 SD; p < 0.001). For
the dose at the isocenter, the PBC-MB calculated a higher
dose in plan 3 than the prescribed dose in plan 1 by on aver-
age 5.2% (1.6 SD; p = 0.002).
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FIG. 2: Transverse views of isodose distribution curves for plan 1 without heterogeneity correction using PBC, and plans 2 and 3 with hetero-
geneity corrections using PBC-MB. A dose of 66Gy was prescribed at isocenter for plan 1 and plan 2. The dose in plan 3 was recalculated using
PBC-MB with the same number of monitor units as in the PBC, and the prescribed dose at isocenter was 68Gy. The yellow contour shows the
PTV, whereas the red, green, and orange colours represent the 100%, 95%, and 40% isodose curves, respectively.
Spatial Isodose distribution
Figure 2 shows the transverse views of isodose distribution
curves for plan 1 (PBC), and plan 2 and plan 3 (PBC-MB). In
figure 2, it can be seen that the 95% isodose curves in all three
plans included the whole PTVs. The 100% isodose curves
enclosed the PTVs using plan 2 and plan 3 to a greater extent
than in plan 1. The 40% isodose curves calculated by PBC-MB
in plan 2 and plan 3 encompassed a greater volume of normal
lung tissue when compared with that of plan 1.
DVH
Figures 3 and 4 show the cDVH and dDVH, rspectively, for a
parenchyma site using the PBC without heterogeneity cor-
rection in plan 1, and the PBC-MB for plans 2 and 3. Tables 2
and 3 summarize the dosimetric and statistical results for the
PTVs and normal lung and the results were averaged for all 6
cases. In tables 2 and 3, it can be seen that the PBC-MB in
plans 2 and 3 calculated a higher dose for the PTVs and
normal lung compared to plan 1. For the normal lung, all
three plans showed the results of V20 and V30 within the
tolerance. For the spinal cord, the maximum dose in plans 2
and 3 was higher by an average of 5% (12 SD) with no statis-
tical significance (p = 0.485). The dose constraint for spinal
cord (maximum dose ≤ 45Gy) was respected in all plans.
The comparison of dDVH showed that the PBC-MB calcu-
lated a heterogeneous dose in plan 2 and plan 3 compared
with PBC in plan 1. The averages of the deviation standard
associated with dDVH were 3.2 Gy (2.1 SD), 3.6 Gy (2.4 SD),
and 3.7 Gy (2.2 SD) for plan 1, plan 2 and plan 3, respective-
ly. There was a significant difference between the dDVH
calculated in plan 1 and plan 2 (p = 0.012), but there was no
significant difference between the dDVH calculated in plan
2 and plan 3 (p = 0.055).
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FIG. 3: Cumulative dose volume histograms for patient 1. The histo-
grams were calculated using the PBC algorithm without tissue het-
erogeneity correction for plan 1 and the PBC-MB method (with
heterogeneity correction) for plans 2 and 3. The dose in plan 3 was
calculated using PBC-MB for the same number of monitor units as
in the PBC for plan 1. The prescription dose for plan 1 and 2 was
66Gy, but it was 68Gy for plan 3.
FIG. 4: Differential dose volume histograms for patient 1. The histo-
grams were calculated using the PBC algorithm without heterogene-
ity correction for plan 1 and the PBC-MB method with heterogene-
ity correction for plans 2 and 3. The dose in plan 3 was calculated
using PBC-MB for the same number of monitor units as in the PBC
for plan 1. The prescription dose for plan 1 and 2 was 66 Gy, but it
was 68 Gy for plan 3.
TABLE 2: Dose-volume parameters derived DHVs for the planning target volume (PTV). The results are averaged over all 6 analyzed cases.
Plans ΔDose % Mean Minimum Maximum D95 V95
2 vs. 1 average ± SD 0.4±1 0.9±3.5 1.9±1.4 1.6±1.8 2.4±4.7
p-value 0.06 0.04 0.01 0.003 0.03
3 vs. 2 average ± SD 3.8 ±2.5 3.9±2.4 2.7 ±2.7 4.6±1.9 8±8
p-value 0.005 0.001 0.02 0.001 <0.001
Δ is the difference of values between plan 2 and plan 1 or plan 3 and plan 2. ΔDose% was calculated according to equations 1 and 2. SD is the
standard deviation. The D95 is the calculated dose to 95% of the PTV volume. The V95 is the volume of PTV receiving at least 95% of the pre-
scribed dose. The p-values were calculated using a Wilcoxon signed rank test. The p-value of less than 0.05 was considered to be statistically
significant.
TABLE 3: Dose volume parameters deriving from dose volume histograms for normal lung tissue (i.e., lung – PTV). The results are averaged over
all 6 analyzed cases.
Plans ΔDose % Mean Minimum Maximum V10 V13 V20 V30
2 vs. 1 average ± SD 8.8±14 1±5.6 1.5±2 4.1±6.2 7.6±17.8 0.5±12.8 0.4±5.2
p-value 0.1 0.1 0.03 0.02 0.1 0.3 0.4
3 vs. 2 average ± SD 5.7±3.6 5.5±3.3 0.8±9.8 2.5±4.7 4.4±5.7 33±47.1 4.6±3.8
p-value 0.001 0.03 0.2 0.1 0.03 0.001 0.03
Δ is the difference of values between plan 2 and plan 1 or plan 3 and plan 2. ΔDose% was calculated according to equations 1 and 2. SD is the
standard deviation. The V10, V13, V20, and V30 Gy are defined as the volume fractions of normal lung receiving 10, 13, 20, and 30 Gy, respec-
tively. The p-values were calculated using a Wilcoxon signed rank test. The p-value of less than 0.05 was considered to be statistically signifi-
cant.
Quality indices
Table 4 summarizes the quality indices for all the PTVs in
plan 1, plan 2, and plan 3. The comparison between plan 1
and plan 2 showed that there was no statistically significant
difference for all the indices, (p > 0.05). The comparison
between plan 2 and plan 3 showed a significant difference for
the geometric indices (p = 0.002).
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TABLE 4: Quality indices in plans 1, 2, and 3. Data are presented as average ± standard deviation. Furthermore, results provided below are av-
eraged over all 6 analyzed cases.
Plans CI HI CIPTV g
Plan 1 0.8 ±0.2 1 ±0.07 0.8 ±0.2 0.2 ±0.2
Plan 2 0.9 ± 0.1 1 ±0.05 0.7 ±0.2 0.2 ±0.2
p-value (2 vs 1) >0.05 >0.05 >0.05 >0.05
Plan 3 0.8 ±0.1 1.1 ±0.1 0.8 ±0.2 0.2 ±0.2
p-value (3 vs 2) >0.05 >0.05 >0.05 0.002
CI is the Conformity Index. HI is the Homogeneity Index. CIPTV is the Conformity Index for the planning target volumes. g is the geometrical
index. The p-values were calculated using a Wilcoxon signed rank test. The p-value of less than 0.05 was considered to be statistically signifi-
cant.
Discussion
There are a wide variety of dose calculation algorithms com-
mercially available for the heterogeneity corrections in radia-
tion therapy.3, 16 Several studies have investigated the change
from PBC to Anisotropic Analytical Algorithm (AAA) for
Eclipse.6, 17, 18, 19, 20, 21 It has been shown that the PBC algorithm
employed with Eclipse TPS could produce errors in dose esti-
mation. Thus, it has been suggested that more accurate calcu-
lation methods are used in clinical radiotherapy planning. In
particular, Rana recommended using more accurate dose cal-
culation in the treatment planning for the lung cancer.22 In our
study, we tackle the problem of changing the calculation algo-
rithms from the PBC without heterogeneity correction to the
PBC with heterogeneity correction. In order to offer clinicians
with treatment plans that are much closer to reality than the
plans generated with the PBC without heterogeneity correc-
tion, we posed the question as to whether the clinician should
adapt the dose prescriptions. Normally, these prescriptions are
the result of decades of clinical experience and are based on
older and less accurate methods of dose calculation. We
strongly suggest that a sufficient number of cases should be
calculated for each anatomical site with the old and the new
algorithms. This is necessary, because we observed that the
differences in calculated dose vary from patient to patient.
Hence, we propose clinicians some recommendations to assist
adaption of the prescribed dose when using new calculation
methods.
In this study, the PBC-MB was used to study the impact of
tissue heterogeneity correction in the lung plans. However, the
PBC-MB is not an accurate correction method since it does not
take into account the changes in lateral electron transport. The
tissue densities introduced a difference between the PBC
without heterogeneity correction and PBC-MB with hetero-
geneity correction. In fact, the lung exhibits the most hetero-
geneous anatomy with bone, lung, and soft tissues. A majority
of lateral and oblique beams pass through the low density tissue
of the lung. For this reason, the heterogeneity correction
showed a dosimetric impact on PTVs and normal lung tissue.
The comparison between plan 1 and plan 2 showed that the
number of MUs was significantly higher in plan 1 compared to
plan 2 using 18 MV photon beams. A comparison of plan 1 and
plan 3, which used the same number of MUs, showed that the
calculated dose was significantly higher in plan 3 compared to
plan 1. The difference in MUs depends on the site location,
PTVs volumes, and field size. This means that the geometric
configuration or the dose weight of beams must be modified to
respect the dose constraints for the normal lung tissues. We
recognize that a limitation of the present study was the small
population number (n = 6).
In practice, clinical dose distributions are not uniform for the
PTVs due to variations in tissue density. The comparison of
dDVH showed that the PBC algorithm without density cor-
rection produced a narrower differential histogram and a larger
number of volume fractions of the PTVs receiving the pre-
scribed dose than for PBC-MB. This means that PBC without
heterogeneity correction tends to give a better PTV coverage.
Nevertheless, the method with the heterogeneity correction is
closer to the reality.16 The use of the PBC-MB produced under
and over estimations of dose for some areas of the PTVs and hot
spots in normal tissue outside the PTVs.
Our results show that the quality indices provide a qualitative
comparison between treatment plans and quantify the degree
of congruence between the isodose and the prescribed dose.
The standard deviation associated with the dDVH provides a
more reliable and accurate measure of dose homogeneity
within the PTVs than the HI. For example, the standard devi-
ations associated with the dDVH were 2.2Gy, 2.9Gy and 3Gy
for plan 1, plan 2 and plan 3 respectively. While HI values were
equal to unity using plan 1 and plan 2, it was 1.1 using plan 3.
We recommend improving the treatment ballistic to take ad-
vantage of the heterogeneity correction methods for the pro-
tection of the OARs by adjustment of target dose prescription,
dose constraints, and evaluation of the tumour control proba-
bility (TCP) and the normal tissue complication probability
(NTCP). Radiobiological treatment plan evaluation of lung
plans could potentially provide more accurate values for the
TCP and NTCP.23
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Conclusion
The method presented in this study enables clinicians and
physicians to understand treatment modifications associated
with changes in dose calculation software. Tissue heterogeneity
correction had a significant impact on dose distribution for the
PTVs and OARs. The number of MUs significantly decreased
using heterogeneity correction PBC-MB. These results should
be discussed among clinicians and medical physicists to decide
whether or not an alteration of the current prescription pro-
cedures and plan acceptability criteria should be considered.
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